Payment overview · 2025
General Payments
$1,781.96
14 reported records · 4 companies
Healthcare provider profile · identity verified
Roger Estevez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1871734178
Verified facts
What the public records show
CMS Open Payments records show Roger Estevez, M.D. received $1,781.96 in general payments during 2025 across 14 reported records.
Merck Sharp & Dohme LLC accounted for 78.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $1,394.43 | 78.2% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $220.19 | 12.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $149.79 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.55 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,135.27 | 4 |
| Food and Beverage | $646.69 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $149.79 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.11 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.08 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 216 |
| Metformin Hcl | Metformin Hcl | 436 | 132 |
| Lisinopril | Lisinopril | 419 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 96 |
| Gabapentin | Gabapentin | 344 | 82 |
| Omeprazole | Omeprazole | 300 | 83 |
| Losartan Potassium | Losartan Potassium | 250 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 236 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 54 |
| Fenofibrate | Fenofibrate | 189 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 51 |
| Ibuprofen | Ibuprofen | 143 | 58 |
| Alendronate Sodium | Alendronate Sodium | 136 | 33 |
| Clonidine Hcl | Clonidine Hcl | 132 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 43 |
| Jardiance | Empagliflozin | 106 | 29 |
| Furosemide | Furosemide | 102 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 19 |
| Alprazolam | Alprazolam | 91 | 19 |
| Carvedilol | Carvedilol | 89 | 22 |
| Glimepiride | Glimepiride | 87 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 82 | 29 |
| Atenolol | Atenolol | 81 | 28 |
| Eliquis | Apixaban | 76 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 24 |
| Farxiga | Dapagliflozin Propanediol | 70 | 25 |
| Diclofenac Sodium Er | Diclofenac Sodium | 68 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Trazodone Hcl | Trazodone Hcl | 64 | 24 |
| Allopurinol | Allopurinol | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 17 |
| Glipizide | Glipizide | 60 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | 15 |
| Famotidine | Famotidine | 57 | 19 |
| Clonazepam | Clonazepam | 53 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 47 |
| Potassium Chloride | Potassium Chloride | 51 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | 18 |
| Nifedipine Er | Nifedipine | 50 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Methocarbamol | Methocarbamol | 48 | 25 |
| Simvastatin | Simvastatin | 46 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Ozempic | Semaglutide | 45 | suppressed |
| Meloxicam | Meloxicam | 44 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 14 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 13 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 30 |
| Linzess | Linaclotide | 35 | 16 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Sertraline Hcl | Sertraline Hcl | 35 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Pentoxifylline | Pentoxifylline | 31 | 13 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,781.96 · 14 records | Merck Sharp & Dohme LLC | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, Symbravo | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error